A study assessed the use of dupilumab for patients with atopic dermatitis (AD) in the real-world setting. The results suggested that dupilumab is well-tolerated and effective in daily practice, “supporting [its] use as chronic therapy for moderate-to-severe AD,” the researchers noted. The results of the study were published as part of the American Academy of Dermatology Virtual Meeting Experience 2020.
In this retrospective, single-center, observational study, researchers conducted a chart review of patients treated for AD at an outpatient dermatology clinic at Oregon Health & Science University who initiated dupilumab between 2016 and 2018.
Drug survival was defined as time from initiation to discontinuation of medication. Researchers measured efficacy via the Investigator Global Assessment (IGA), Patient Global Assessment (PtGA), and body surface area x IGA at baseline and 16 and 52 weeks.
A total of 61 patients were included in the study; patients were on dupilumab for a mean 13.28 months. Mean drug survival rates were 90.1% (95% confidence interval [CI], 77.7-95.8) at 12 months and 81.2% (95% CI, 60.7-91.7) at 24 months. Median survival was not achieved during the study.
At 16 weeks, 29.4% of patients achieved clear or almost clear skin, per IGA; at 52 weeks, 43.3% of patients achieved clear or almost clear skin. At 16 and 52 weeks, 38.2% and 50.0% of patients, respectively, self-reported their disease as mild, per PtGA.
Seven patients discontinued treatment, representing a 11.5% discontinuation rate. Reasons for discontinuation were financial (defined as loss of insurance; n=3; 42.9%), controlled AD (n=2; 28.6%), conjunctivitis (n=1; 14.3%), and “other” (n=1; 14.3%).
The study is limited by its small sample size and non-mandatory follow-up.
Brazil M, Topham C, Haynes D, et al. Real-World Effectiveness and Drug Survival of Dupilumab: A Single-Center Retrospective Analysis. Presented during the AAD Virtual Meeting Experience 2020, June 12-14, 2020.